Physiomics, ValiRx deal

Physiomics will use its Virtual Tumour model technology to predict the ideal treatment regimens of VAL201 from ValiRx's ValiPharma Ltd. subsidiary for Phase I testing. Physiomics will not receive an upfront payment but will be eligible for an undisclosed percentage of any licensing income for use of VAL201 in prostate cancer treatment. ValiPharma will retain IP and commercialization rights to VAL201. Virtual Tumour simulates the effects of treatments on cell behavior. Details were not disclosed. ...